A multicenter collaborative study on infantile onset facioscapulohumeral muscular dystrophy

Yi-Wen Chen, DVM, PhD

Associate Professor of Pediatrics and Integrative Systems Biology
Children’s National Medical Center and George Washington University

2014 FSHD Connect Meeting, Boston
August 16-17th 2014
Infantile onset of FSHD

- Facial weakness <5 yrs and shoulder girdle weakness <10 yrs (Brouwer et al, 1994)
- Retinal vasculopathy
- Sensorineural hearing loss
- Epilepsy
- Mental retardation
Study objectives

1. Establish a standardized muscle testing protocol including both manual and quantitative muscle testing as well as function testing for use in children and adults with infantile onset FSHD

2. Describe the clinical phenotypes of infantile FSHD

3. Evaluate the impact of physical impairment, secondary health conditions, activity limitations and disability caused by FSHD on health-related quality of life and disability across different age groups; as well as to evaluate the utility of the FSHD clinical severity scale
Study objectives

4. Investigate for potential genetic modifiers of clinical phenotypes and disease progression in infantile FSHD. The correlation between gene expression and disease severity will be evaluated.

5. Identify biomarker candidates for infantile FSHD for evaluations of therapeutic efficacy in future clinical studies.
Study Chair - Jean K. Mah, MD, MSc
Alberta Children's Hospital

Co-chair - Yi-Wen Chen, DVM, PhD
Children’s National Medical Center (CNMC)
George Washington University

Lauren Hache (CINRG)
Phone: 412-224-2030
Email: lhache@childrensnational.org
The Cooperative International Neuromuscular Research Group (CINRG)

www.cinrgresearch.org
CINRG

- Founded in 1999 at Children’s National Health System

- Multi-disciplinary and cross-institutional network of clinicians and scientists wishing to positively impact the lives of patients with neuromuscular disorders via research studies

- Study the cause(s), pathogenesis and clinical outcomes of neuromuscular disorders and conduct well-controlled clinical studies
CINRG Coordinating Center

• Housed within the Center for Genetic Medicine Research at Children’s National Medical Center with elements spread over a selected group of centers

• Directors:
  – Coordinating Center: Dr. Avital Cnaan
  – Medical: Dr. Paula Clemens
  – Scientific: Dr. Eric Hoffman
## CINRG Completed Studies

<table>
<thead>
<tr>
<th>Study Title</th>
<th>Study Chair</th>
<th>Sponsor</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double Blind RTC of Daily Pentoxifylline as Rescue Treatment in DMD</td>
<td>D. Escolar</td>
<td>FED</td>
<td>Neurology (2012) 78;904-913</td>
</tr>
<tr>
<td>Comparative Study of Clinical Endpoint: HHM vs. CQMS</td>
<td>T. Duong</td>
<td>MDA</td>
<td>Manuscript in preparation</td>
</tr>
<tr>
<td>Evaluation of LGMD</td>
<td>S. Sparks</td>
<td>MDA</td>
<td>Manuscript in preparation</td>
</tr>
<tr>
<td>Cardiac Outcome Measures in Children with Muscular Dystrophy</td>
<td>P. Clemens</td>
<td>NIH</td>
<td>Manuscript in preparation</td>
</tr>
</tbody>
</table>
CINRG Clinical Research Network
27 SITES

Disease Census
- Duchenne: ~ 3,000 pts
- Becker: ~ 600 pts
- FSHD: ~ 500 pts
- LGMD: ~ 320 pts known type ~ 600 pts unknown type

All centers are major neuromuscular referral centers
CINRG Clinical Site Locations

US Sites

- Children’s National Medical Center, Washington, DC
- Children's Hospital, Richmond, VA
- University of Pittsburgh, Pittsburgh, PA
- University of Tennessee, Memphis, TN
- University of Puerto Rico, San Juan, PR
- Washington University - St. Louis, MO
- Mayo Clinic, Rochester, MN
- University of California - Davis, Sacramento, CA
- Texas Children's Hospital, Houston, TX
- University of Minnesota, Minneapolis, MN
- Carolinas Medical Center, Charlotte, NC
- Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
- Duke Medical Center, Durham, NC

International Sites

- Hadassah, Hebrew University Hospital, Jerusalem, Israel
- Holland Bloorview Kids Rehab, Toronto, Canada
- Apollo Hospitals, Chennai, India
- Royal Children's Hospital, Melbourne, Australia
- Fundacion Favaloro, Buenos Aires, Argentina
- Queen Silvia Children's, Göteborg, Sweden
- Children's Hospital at Westmead, Sydney, Australia
- Alberta Children's Hospital, Calgary, Canada
- University of Alberta, Edmonton, Canada
- Centro Clinico NeMO Hospital, Milan, Italy
- National Center of Neurology and Psychiatry, Tokyo, Japan
- Kobe University, Kobe, Japan
- Newcastle University, Newcastle upon Tyne, UK
CINRG Site Personnel

Each site team has the following minimum staff:

• Site Principal Investigator
• Clinical Research Coordinator
  – Coordinate study visits
• Two Physical Therapists
  – Trained and certified as Clinical Evaluators for CINRG
  – Performs CQMS tests
CINRG Quantitative Measurement System (CQMS)

- Over 50 physical therapists certified through reliability training on commonly used clinical trial endpoints in NMD
- Harmonization of outcomes
- Standardization of equipment
Study Design/Enrollment

• Recruit 50 participants with infantile onset FSHD across all centers

• Average enrollment is 3 participants per site but we encourage sites to enroll to their maximum capability

• Complete enrollment within a 12 months period (estimated enrollment closure Winter 2014)
Inclusion Criteria

The presence of all of the following features based on review of medical records and/or direct examination:

• Onset of symptoms involving the facial or shoulder girdle muscles at or younger than 10yr, and

• Autosomal dominant inheritance in familial cases, and

• Contraction of the D4Z4 repeat array from 1–10 (10 – 38 kb) copies in the 4q35 subtelomeric region, based on established molecular genetic techniques.
Exclusion Criteria

- Symptomatic cardiomyopathy or severe cardiac arrhythmia which may limit the ability to complete the study protocol

- Maternal mode of inheritance (also referred to as mitochondrial inheritance)

- Evidence of an alternative diagnosis based on muscle biopsy or other available investigations

- In the Investigator's opinion an inability to comply with the protocol
**Study Assessments**

- Physicians Assessments (approximately 30 min)
- Cognitive assessments (approximately 30 min) – Age restrictions in areas
- Standardized Self-Administered Questionnaires (approximately 30 min)
- Clinical Evaluator Assessments (approximately 140 min) - Age restrictions in areas
Study Assessments

Sub-Specialties (Optional Based on Site Resources)

• Hearing Assessment (approximately 30 min)

• Ophthalmologic Assessment (approximately 60 min)

• Speech Assessment (approximately 30 min) - Age restrictions in areas

Optional Participant Assessment

• Blood Sample Collection (approximately 10 min)
Funding Support

- FSH Society (USA)
- Muscular Dystrophy Canada (Canada)
- FSHD Global Research Foundation (Australia)